-
ProductsRealizing the Concept of "Practitioner of Precision Medicine"
-
SolutionOne-stop Space Biology Solution for Multi-application Scenarios
-
Technical ServicesPerfect multi-omics (DNA\RNA \protein) detection platform
-
About UsBeijing Fino Weikang Biotechnology Co., Ltd.
-
Consulting Dynamics
Drug development
Application scenarios
1. Evaluation of immunotherapy efficacy
Compared with NGS, RNA-seq, immunohistochemistry and other methodologies, the evaluation of immune therapy is more accurate.
2. Immune-polyvalent drug testing
· Clinical PD-L1 combined with CTLA-4 neoadjuvant therapy
· ·PD-L1, CTLA-4, CD20, and CD8 were used to evaluate immunotherapy efficacy in patients
3. Molecular typing of diseases
According to the expression of tumor tissue PD-L1 and tumor infiltrating lymphocytes (TIL), tumors can be divided into 4 immune phenotypes, and Type II is the ideal type of PD-1/PD-L1 inhibitor.
Floor 3, Unit 1, Building 15, Jiajie Box Enterprise Exchange, Daxing District, Beijing
Official public number two-dimensional code
